公开(公告)号：EP3178938A4

公开(公告)日：2018-03-21

申请号：EP15829016

申请日：2015-08-06

申请人： GRUPO IND PECUARIO S A DE C V

发明人： LOZANO DUBERNARD BERNARDO ,  SOTO PRIANTE ERNESTO ,  SARFATI MIZRAHI DAVID

IPC分类号： C12N15/861 ,  A61K39/112 ,  A61K39/12 ,  A61K39/145 ,  A61K39/215 ,  A61K39/245

CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10221 ,  C12N2710/10234 ,  C12N2710/10243 ,  C12N2710/10271 ,  C12N2710/16034 ,  C12N2710/16071 ,  C12N2760/16134 ,  C12N2760/16171

摘要： A recombinant vaccine comprising a serotype 9 fowl adenovirus vector (FAdV-9) having at least one exogenous nucleotide sequence inserted encoding at least one antigen of a disease of interest and replacing the adenovirus genome non-essential region, and a pharmaceutically acceptable vehicle, adjuvant and/or excipient, wherein the at least one exogenous nucleotide sequence encoding at least one antigen of a disease of interest and replacing the adenovirus genome non-essential region is located between the 491 and 2782 nucleotides. The vector of this vaccine is stable for industrial scale production. Likewise, even when this vaccine is administered in combination with a vaccine against Marek's disease, both vaccines produce an adequate immune response which is not affected by interference between each other. In the same way, effectiveness of the recombinant vaccine is not affected by maternal antibodies, and is capable of inducing both an early and lasting protective response, even with only one application.

公开(公告)号：EP3263130A1

公开(公告)日：2018-01-03

申请号：EP17181500.4

申请日：2012-11-29

申请人： Merial, Inc.

发明人： BUBLOT,, Michel ,  MEBATSION,, Teshome ,  PRITCHARD,, Joyce ,  LINZ,, Perry

IPC分类号： A61K39/12

CPC分类号： A61K39/12 ,  A61K2039/5256 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/70 ,  C12N2710/16034 ,  C12N2710/16041 ,  C12N2710/16071 ,  C12N2710/16343 ,  C12N2720/00034 ,  C12N2720/10034 ,  C12N2760/18134

摘要： The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.

公开(公告)号：EP2852662A4

公开(公告)日：2016-02-10

申请号：EP13793902

申请日：2013-05-21

申请人： SANOFI PASTEUR LTD ,  SANOFI PASTEUR BIOLOGICS LLC

发明人： ANDERSON STEPHEN ,  DELAGRAVE SIMON ,  HAMBERGER JOHN ,  LI QINGLIAN ,  MUNDLE SOPHIA ,  RAHMAN NAUSHEEN

IPC分类号： A61K39/12 ,  C12N7/00

CPC分类号： A61K39/245 ,  A61K9/0019 ,  A61K39/12 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2710/16034 ,  C12N2710/16611 ,  C12N2710/16634 ,  C12N2710/16651

摘要： The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.

公开(公告)号：EP2016182B1

公开(公告)日：2015-07-08

申请号：EP07732664.3

申请日：2007-05-04

申请人： Virttu Biologics Limited

发明人： CONNER, Joe

IPC分类号： C12N15/869

CPC分类号： C12N15/86 ,  C12N15/869 ,  C12N15/8695 ,  C12N2710/16034 ,  C12N2710/16041 ,  C12N2710/16061 ,  C12N2710/16611 ,  C12N2710/16634 ,  C12N2710/16643 ,  C12N2710/16651

公开(公告)号：EP2782597A1

公开(公告)日：2014-10-01

申请号：EP12851895.8

申请日：2012-11-21

申请人： Genocea Biosciences Inc.

发明人： LONG, Deborah ,  FLECHTNER, Jessica ,  SKOBERNE, Mojca

IPC分类号： A61K39/245 ,  C12N15/38 ,  C07K14/035 ,  A61P31/22

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/53 ,  A61K2039/55538 ,  A61K2039/55577 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/16034 ,  C12N2710/16622 ,  C12N2710/16634

摘要： Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides,
inter alia , certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.

公开(公告)号：EP2516629A4

公开(公告)日：2013-09-04

申请号：EP10840033

申请日：2010-12-20

申请人： BRIGHAM & WOMENS HOSPITAL

发明人： YAO FENG

IPC分类号： C12N7/04 ,  A61K38/16 ,  A61K39/245 ,  A61K39/395

CPC分类号： A61K39/245 ,  A61K35/763 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/57 ,  C12N7/00 ,  C12N15/869 ,  C12N15/8695 ,  C12N2710/16011 ,  C12N2710/16021 ,  C12N2710/16034 ,  C12N2710/16062 ,  C12N2710/16071 ,  C12N2710/16611 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16634 ,  C12N2710/16661 ,  C12N2710/16662 ,  C12N2830/003 ,  C12N2830/006 ,  G01N33/56994

公开(公告)号：EP0974659B1

公开(公告)日：2009-02-11

申请号：EP99114400.7

申请日：1989-09-13

申请人： MERIAL

发明人： Griffin, Annette Mary ,  Ross, Louis Joseph Norman ,  Scott, Simon David ,  Binns, Matthew McKinley

IPC分类号： C12N15/38 ,  C07K14/03 ,  C12N15/86 ,  A61K39/245

CPC分类号： C12N15/86 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K39/255 ,  A61K2039/51 ,  A61K2039/5254 ,  A61K2039/5256 ,  C07K14/005 ,  C12N9/0093 ,  C12N9/1211 ,  C12N15/00 ,  C12N2710/16022 ,  C12N2710/16034 ,  C12N2710/16043 ,  C12N2710/16322 ,  C12N2710/16334 ,  C12N2710/16343

公开(公告)号：EP1578959A1

公开(公告)日：2005-09-28

申请号：EP03780585.0

申请日：2003-12-22

申请人： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  Ministry of Agricultural and Rural Development Dept. of Fisheries and Aquaculture

发明人： KOTLER, Moshe ,  BENET, Ayana ,  BEJERANO, Izhak ,  CHEN, Nissim ,  HUTORAN, Marina ,  RONEN, Ariel

IPC分类号： C12N7/00 ,  C12N7/08 ,  A61K39/245 ,  G01N33/569 ,  C07K16/08

CPC分类号： C12N7/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/55566 ,  C12N2710/00021 ,  C12N2710/00034 ,  C12N2710/00064 ,  C12N2710/16034 ,  G01N2333/03

摘要： The present invention provides the isolated causative agent of the disease affecting Cyprinus carpino and a method for its isolation. The invention further provides avirulent forms, e.g., live-attenuated form, inactivated form and genetically modified forms of the virus which may be used for vaccination of susceptible fish.

公开(公告)号：EP1523992A1

公开(公告)日：2005-04-20

申请号：EP04021994.1

申请日：1997-07-16

申请人： MERIAL

发明人： Audonnet, Jean-Christophe ,  Bouchardon, Annabelle ,  Riviere, Michel

IPC分类号： A61K39/12

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/17 ,  A61K39/215 ,  A61K39/245 ,  A61K39/255 ,  A61K2039/51 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/70 ,  C12N2710/16034 ,  C12N2710/16334 ,  C12N2720/10034 ,  C12N2750/10034 ,  C12N2760/16134 ,  C12N2760/18134 ,  C12N2760/18334 ,  C12N2770/20034 ,  C12N2770/22034 ,  C12N2770/32034 ,  C12N2770/32434

摘要： La présente invention concerne des formules de vaccin aviaire contre la maladie de Gumboro.

摘要翻译： 本发明涉及用于冈博尔病的禽类疫苗制剂。

公开(公告)号：EP1470218A2

公开(公告)日：2004-10-27

申请号：EP02738952.7

申请日：2002-05-17

申请人： Universiteit Utrecht ,  STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN

发明人： ROTTIER, Petrus, Josephus, Marie ,  DE HAAN, Cornelis, Alexander, Maria ,  HAIJEMA, Bert, Jan ,  BOSCH, Berend, Jan

IPC分类号： C12N7/04 ,  C12N15/86 ,  A61K39/215 ,  A61K39/225 ,  C07K14/165

CPC分类号： A61K39/215 ,  A61K38/00 ,  A61K39/12 ,  A61K39/225 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/12034 ,  C12N2710/16034 ,  C12N2740/13034 ,  C12N2750/14334 ,  C12N2760/16034 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2770/20034 ,  C12N2770/20043 ,  C12N2800/204 ,  G01N33/56983 ,  G01N2333/165

摘要： The invention relates to the field of coronaviruses and diagnosis, therapeutic use and vaccines derived thereof. The invention provides replicative coronaviruses and replicative virus-like particles (VLPs) from which large parts of their genome are (at least functionally) deleted without abolishing their replicative capacities. Said deletion is preferably resulting in at least a functional deletion in that the corresponding gene is not or only partly expressed whereby the resulting gene product is dysfunctional or at least functionally distinct from a corresponding wild-type gene product. One striking result seen with VLPs provided with deletions as provided herein is that said deleted VLP, albeit capable of replication in vitro and in vivo, are in general well attenuated, in that they do not cause disease in the target host, making them very suitable for therapeutic use, said as a delivery vehicle for genes and other cargo (whereby specific targeting may be provided as well when desired), and for use as a vaccine, being attenuated while carrying important immunogenic determinants that help elicit an immune response.